Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Agreement between Amgen/Novartis and Eli Lilly with Express Scripts on new migraine drugs could spur more demand by payers for simple, value-based outcomes deals.

SC1810_Headache_550907356_1200.jpg

Teva Pharmaceutical Industries Ltd. is defending the commercial strategy for its migraine drug Ajovy after Express Scripts Holding Co. excluded the drug from its formulary in favor of rival calcitonin gene-related peptide (CGRP) inhibitors – Amgen Inc./Novartis AG' Aimovig and Eli Lilly & Co.'s Emgality – with a new reimbursement program that includes a refund from sponsors if patients drop out of therapy in the first 90 days.

The pharmacy benefit manager (PBM) announced Oct. 17 that its new SafeGuardRX Migraine Care Value program – to be launched...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip